Department of Epidemiology and Cancer Control, St. Jude Children's Research Hospital, 262 Danny Thomas Place, Memphis, TN 38105, USA.
Expert Rev Hematol. 2011 Apr;4(2):185-97. doi: 10.1586/ehm.11.8.
Survival of childhood acute lymphoblastic leukemia (ALL) is one of the greatest medical success stories of the last four decades. Unfortunately, childhood ALL survivors experience medical late effects that increase their risk of morbidity and premature death, often due to heart and vascular disease. Research has helped elucidate the mechanisms and trajectory of direct damage to the heart from treatment exposure, particularly to anthracyclines, and has also contributed knowledge on the influences of related chronic conditions, such as obesity and insulin resistance on heart health in these survivors. This article summarizes the key issues associated with early morbidity and mortality from cardiac-related disease in childhood ALL survivors and suggests directions for interventions to improve long-term outcomes.
儿童急性淋巴细胞白血病(ALL)的存活率是过去四十年中最伟大的医学成功案例之一。不幸的是,ALL 幸存者会出现医疗后期效应,增加其发病和过早死亡的风险,这通常是由于心脏和血管疾病引起的。研究有助于阐明治疗暴露(特别是蒽环类药物)对心脏直接损伤的机制和轨迹,也有助于了解相关慢性疾病(如肥胖和胰岛素抵抗)对这些幸存者心脏健康的影响。本文总结了与儿童 ALL 幸存者心脏相关疾病的早期发病率和死亡率相关的关键问题,并为改善长期预后的干预措施提出了建议。